Biodesix said this week that data from an analysis of serum and plasma samples from a Phase II non-small cell lung cancer study demonstrate that its Veristrat test is able to identify patients likely to benefit when treated with erlotinib – marketed by Roche as Tarceva – and erlotinib combined with gemcitabine.

The results were presented this week at the Chicago Multidisciplinary Symposia in Thoracic Oncology by Thomas Stinchcombe, associate professor of hematology/oncology at the University of North Carolina Lineberger Comprehensive Cancer Center.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.